Esperion Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI, 48108
Mailing Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI, 48108
Phone
734-887-3903
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$767.85M
Total Liabilities
$-0.11
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 2, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | March 18, 2026 | View on SEC |
| 4 Insider stock transaction report | March 18, 2026 | View on SEC |
| 4 Insider stock transaction report | March 18, 2026 | View on SEC |
| 4 Insider stock transaction report | March 16, 2026 | View on SEC |
| 4 Insider stock transaction report | March 16, 2026 | View on SEC |
| 4 Insider stock transaction report | March 16, 2026 | View on SEC |
| 8-K Current report of material events | March 10, 2026 | View on SEC |
| 10-K Annual financial report | March 10, 2026 | View on SEC |
Annual Reports
10-K
March 10, 2026
- Esperion reported a 20% revenue growth in 2025, reaching $125 million, driven by increased product adoption.
- The company significantly reduced its net loss from $180 million in 2024 to $150 million in 2025, signaling improved financial efficiency.
Material Events
8-K
Acquisition
April 2, 2026
High Impact
- Strategic expansion into heart care via the acquisition of Corstasis Therapeutics.
- Addition of Enbumyst™, the only FDA-approved nasal spray for fluid buildup in heart failure patients.
Insider Trading
SELL
3 insiders
7 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.